Completed PHASE1 INTERVENTIONAL 6-arm NCT00971633

A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)

An Open-Label, Randomized, Single Dose, 3-period Crossover Study to Determine the Bioequivalence of 3 Formulations of Ondansetron in Healthy Young Adult Male and Female Subjects

Sponsor: Merck Sharp & Dohme LLC

Conditions Chemotherapy-Induced Nausea and Vomiting

Interventions Comparator: Treatment A (Zofran, ondansetron) Comparator: Treatment B (Zofran, ondansetron) Comparator: Treatment C (Zofran, ondansetron)

Updated 9 times since 2017 Last updated: Sep 13, 2016 Started: Nov 30, 2003 Primary completion: Dec 31, 2003 Completion: Jan 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00971633, this PHASE1 trial focuses on Chemotherapy-Induced Nausea and Vomiting and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 9 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jun 2022 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.